Page 53 - Read Online

Page 8 of 9 Akabane et al. Hepatoma Res 2023;9:29 https://dx.doi.org/10.20517/2394-5079.2023.45

DOI PubMed PMC
20. Sapisochin G, Fidelman N, Roberts JP, Yao FY. Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in
patients undergoing transplantation for hepatocellular carcinoma. Liver Transpl 2011;17:934-42. DOI PubMed
21. Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and prognosis for patients with intrahepatic
cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg 2014;149:565-74. DOI PubMed
22. Reese T, Pagel G, Bause BA, von Rittberg Y, Wagner KC, Oldhafer KJ. Complex liver resections for intrahepatic
cholangiocarcinoma. J Clin Med 2021;10:1672. DOI PubMed PMC
23. Mullen JT, Ribero D, Reddy SK, et al. Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major
hepatectomy. J Am Coll Surg 2007;204:854-62; discussion 862. DOI
24. Hackl C, Schlitt HJ, Renner P, Lang SA. Liver surgery in cirrhosis and portal hypertension. World J Gastroenterol 2016;22:2725-35.
DOI PubMed PMC
25. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118
studies. J Hepatol 2006;44:217-31. DOI PubMed
26. Gerber DA. Safely expanding surgical resection for patients with hepatocellular carcinoma and cirrhosis. Dig Med Res 2020;3:24-24.
DOI
27. Abbas N, Fallowfield J, Patch D, et al. Guidance document: risk assessment of patients with cirrhosis prior to elective non-hepatic
surgery. Available from: https://discovery.ucl.ac.uk/id/eprint/10167962 [Last accessed on 6 Jul 2023].
28. Coelho FF, Kruger JA, Fonseca GM, et al. Laparoscopic liver resection: experience based guidelines. World J Gastrointest Surg
2016;8:5-26. DOI PubMed PMC
29. Hyder O, Hatzaras I, Sotiropoulos GC, et al. Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery
2013;153:811-8. DOI PubMed PMC
30. Spolverato G, Vitale A, Cucchetti A, et al. Can hepatic resection provide a long-term cure for patients with intrahepatic
cholangiocarcinoma? Cancer 2015;121:3998-4006. DOI
31. Lang H, Sotiropoulos GC, Sgourakis G, et al. Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158
patients. J Am Coll Surg 2009;208:218-28. DOI
32. Friedman LS. Surgery in the patient with liver disease. Trans Am Clin Climatol Assoc 2010;121:192-204. PubMed PMC
33. Lieser MJ, Barry MK, Rowland C, Ilstrup DM, Nagorney DM. Surgical management of intrahepatic cholangiocarcinoma: a 31-year
experience. J Hepatobiliary Pancreat Surg 1998;5:41-7. DOI PubMed
34. Park J, Kim MH, Kim KP, et al. Natural history and prognostic factors of advanced cholangiocarcinoma without surgery,
chemotherapy, or radiotherapy: a large-scale observational study. Gut Liver 2009;3:298-305. DOI PubMed PMC
35. Valle J, Wasan H, Palmer DH, et al; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract
cancer. N Engl J Med 2010;362:1273-81. DOI
36. Konstantinidis IT, Groot Koerkamp B, Do RK, et al. Unresectable intrahepatic cholangiocarcinoma: systemic plus hepatic arterial
infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer 2016;122:758-65.
DOI PubMed PMC
37. André T, Tournigand C, Rosmorduc O, et al; GERCOR Group. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary
tract adenocarcinoma: a GERCOR study. Ann Oncol 2004;15:1339-43. DOI
38. Constance D, Mairead GM, Samuel LS, et al. Influence of cirrhosis on outcomes of patients with advanced intrahepatic
cholangiocarcinoma receiving chemotherapy. J Clin Oncol 2022;40:4_suppl, 475. DOI
39. Ueno M, Ikeda M, Morizane C, et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with
unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. Lancet Gastroenterol Hepatol
2019;4:611-21. DOI PubMed
40. Ziogas IA, Giannis D, Economopoulos KP, et al. Liver transplantation for intrahepatic cholangiocarcinoma: a meta-analysis and meta-
regression of survival rates. Transplantation 2021;105:2263-71. DOI
41. Wang Z, Cao YJ. Adoptive cell therapy targeting neoantigens: a frontier for cancer research. Front Immunol 2020;11:176. DOI
PubMed PMC
42. Jindal V, Arora E, Masab M, Gupta S. Chimeric antigen receptor T cell therapy in pancreatic cancer: from research to practice. Med
Oncol 2018;35:84. DOI PubMed
43. Vignone A, Biancaniello F, Casadio M, et al. Emerging therapies for advanced cholangiocarcinoma: an updated literature review. J
Clin Med 2021;10:4901. DOI PubMed PMC
44. Kuhlmann JB, Euringer W, Spangenberg HC, et al. Treatment of unresectable cholangiocarcinoma: conventional transarterial
chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. Eur J
Gastroenterol Hepatol 2012;24:437-43. DOI
45. Borakati A, Froghi F, Bhogal RH, Mavroeidis VK. Stereotactic radiotherapy for intrahepatic cholangiocarcinoma. World J
Gastrointest Oncol 2022;14:1478-89. DOI PubMed PMC
46. Takahashi K, Obeid J, Burmeister CS, et al. Intrahepatic cholangiocarcinoma in the liver explant after liver transplantation: histological
differentiation and prognosis. Ann Transplant 2016;21:208-15. DOI
47. Giorgio A, Calisti G, DE Stefano G, et al. Radiofrequency ablation for intrahepatic cholangiocarcinoma: retrospective analysis of a
single centre experience. Anticancer Res 2011;31:4575-80. PubMed